News

FOLFOXIRI and Panitumumab in mCRC Treatment – Improvement in Treatment Response and Metastasis Resectability
For patients with metastatic colorectal cancer (mCRC) who are able to undergo intensive treatment, the FOLFOX (5-fluorouracil/leucovorin, oxaliplatin) or FOLFIRI (5-fluorouracil/leucovorin, irinotecan) regimens combined with monoclonal antibodies represent the standard first-line treatment. The FOLFOXIRI regimen, which is another option, was developed to further enhance the efficacy of chemotherapy. The German oncologists' VOLFI study investigated the effectiveness of combining targeted therapy and triplet chemotherapy compared to chemotherapy…

Early Cytoreductive Treatment Delays Onset of Symptoms Associated with Metastatic Colorectal Carcinoma

Itoprid helps diabetics with reduced gastrointestinal motility improve diabetes control

Effect of Itopride on Esophageal Motility and Lower Esophageal Sphincter Function

Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?

Educational Quiz (For Downtime)

Significant Reduction in the Extent and Intensity of Psoriasis After Initiating Therapy with Skin Foam − Case Study

Brodalumab – 5 Years of Data on Efficacy, Safety, and Quality of Life Improvement in Plaque Psoriasis

Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy

Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia
Conferences
News from the world of medicine
All conferences
Popular this week
- How Do Chronic and Acute Stress Affect the Gastrointestinal Tract?
- AI Could Transform Cancer Treatment by Precisely Identifying Tumor Cells
- Why Do We Forget About the Nocebo Effect, Even Though It Is Stronger Than the Placebo Effect?
- “Clinical Bites” – Research Highlights 2025/28
- Europe Reads DNA: Genomic Projects Shaping the Future